Duchenne Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Duchenne Muscular Dystrophy stocks.

Duchenne Muscular Dystrophy Stocks Recent News

Date Stock Title
May 31 SMMT Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
May 31 SMMT Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
May 31 SRPT Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
May 31 SMMT Summit Therapeutics Stock: Plunging Despite A Win?
May 31 SMMT Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda
May 31 SMMT Summit reports data from Phase III NSCLC treatment trial
May 30 SMMT Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30 SMMT Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda
May 30 SMMT Competitor to Merck's Keytruda Worries Some Investors
May 30 SMMT Summit lead asset beats Merck’s Keytruda in a first in lung cancer
May 30 SMMT Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
May 30 WVE Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
May 30 DYN Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30 SRPT Sarepta Therapeutics set to join S&P MidCap 400
May 29 SRPT Sarepta Therapeutics Set to Join S&P MidCap 400
May 29 SRPT Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?
May 28 TVTX Travere gains on Novartis data for Filspari rival, Calliditas buyout
May 28 SRPT RBC Capital cuts Sarepta to sector perform ahead of FDA decision
May 28 SMMT Why Summit Therapeutics Stock Is Sinking Today
Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy. The symptom of muscle weakness usually begins around the age of four in boys and worsens quickly. Typically muscle loss occurs first in the upper legs and pelvis followed by those of the upper arms. This can result in trouble standing up. Most are unable to walk by the age of 12. Affected muscles may look larger due to increased fat content. Scoliosis is also common. Some may have intellectual disability. Females with a single copy of the defective gene may show mild symptoms.The disorder is X-linked recessive. About two thirds of cases are inherited from a person's mother, while one third of cases are due to a new mutation. It is caused by a mutation in the gene for the protein dystrophin. Dystrophin is important to maintain the muscle fiber's cell membrane. Genetic testing can often make the diagnosis at birth. Those affected also have a high level of creatine kinase in their blood.Although there is no known cure, physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells.DMD affects about one in 5,000 males at birth. It is the most common type of muscular dystrophy. The average life expectancy is 26; however, with excellent care, some may live into their 30s or 40s. Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags